The tPAD is a non-significant risk device which is composed of a 510K approved Aerogen Aeroneb Pro vibrating mesh nebulizer with a custom nebulization chamber that allows for connection of a standard nasal cannula. Protocol PS-D201 is funded by NIH Grant 2R44HL110502-02 "Hypertonic Saline for Cystic Fibrosis".